Owkin, Boehringer Ingelheim Sign AI Drug Development Licensing Agreement on September 2
According to Guru Club, artificial intelligence company Owkin and German pharmaceutical firm Boehringer Ingelheim signed a licensing agreement on September 2. Under the deal, Boehringer Ingelheim will use Owkin's AI research platform and patient data to accelerate the development of cancer and
GateNews·09-02 13:30
